In this podcast from the DPHARM 2024 archives, Biogen discussed pilots in which they used an AI-enabled software to detect cognitive impairment and Alzheimer’s disease neuropathology, based on voice, to provide access to patients with a clinically validated cognitive assessment who might not otherwise have the foundation to start a conversation with their physician about their cognition, and to reduce the burden of pre-screening.
For more information, go to DPHARMconference.com.
Speakers
Katie King, MSHS
Associate Director, PCE DU Lead AD, Patient Centricity & Engagement, Global Clinical Operations
Biogen
Andrew Vigario, MA
Senior Clinical Country & Site Lead
Biogen
This content was created by The Conference Forum staff. The Fierce editorial team did not contribute to this work.